Expression of circulating microRNA in chronic heart failure in patients with cardiovascular pathologies

Kochetov A.G.

Tsentr kardiokhirurgii i tsentr urologii 3-go Tsentral'nogo voennogo klinicheskogo gospitalia im. A.A. Vishnevskogo MO RF, Moskovskaia oblast', Krasnogorsk

Lyang O.V.

Assotsiatsija spetsialistov i organizatsij laboratornoj sluzhby «Federatsija laboratornoj meditsiny», 127083 Moskva, ul. 8 Marta, 1, str.12

Gimadiev R.R.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare of the Russian Federation

Abramov A.A.

National Cardiology Research Center, Russian Ministry of Health, 3 Cherepkovskaya 15A, Moscow, 121552, Russian Federation

Zhirov I.V.

National medical research center of cardiology MH RF

Skvortsov A.A.

Federal State Budget Organization National Medical Research Center of Cardiology, Ministry of Healthcare Russian Federation, Moscow, Russia

Zaseeva A.V.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare of the Russian Federation

Bosykh E.G.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare of the Russian Federation

Masenko V.P.

National Medical Research Center of Cardiology, Ministry of Healthcare of Russia

Tereshchenko S.N.

National medical research center of cardiology MH RF

Expression of circulating microRNA in chronic heart failure in patients with cardiovascular pathologies

Authors:

Kochetov A.G., Lyang O.V., Gimadiev R.R., Abramov A.A., Zhirov I.V., Skvortsov A.A., Zaseeva A.V., Bosykh E.G., Masenko V.P., Tereshchenko S.N.

More about the authors

Journal: Laboratory Service. 2016;5(1): 26‑32

DOI: 10.17116/labs20165126-32

Downloaded: 18

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kochetov AG, Lyang OV, Gimadiev RR, et al. . Expression of circulating microRNA in chronic heart failure in patients with cardiovascular pathologies. Laboratory Service. 2016;5(1):26‑32. (In Russ.)
https://doi.org/10.17116/labs20165126-32

Close metadata

Recommended articles:

Cardiotropic effect of natural nitric oxide donor in doxorubicin cardiomyopathy. Russian Cardiology Bulletin. 2024;(2):27-31

Left ventricular reverse remodeling after transcatheter mitral valve repair in a patient with ischemic cardiomyopathy. Russian Cardiology Bulletin. 2024;(2):72-80

Impact of SGLT2 inhibitors on erythropoiesis and iron exchange in patients with diabetes mellitus and chronic heart failure. Russian Journal of Preventive Medicine. 2024;(5):103-110

Regulatory miRNA21, miRNA92, miRNA221 and miRNAlet7 expression in carotid and coronary atherosclerotic plaques. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(3):245-252

Implantation of left ventricular assist device in a child with small body surface area. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(3):317-320

Cost-effectiveness analysis of HeartMate3 system in patients with severe chronic heart failure and reduced left ventricular ejection fraction. Medical Technologies. Assessment and Choice. 2024;(2):78-89

Evaluation of clinical efficacy and efficiency of new anticoagulants and sodium-glucose cotransporter 2 inhibitors in patients with coronary artery disease and concomitant cardiovascular diseases. Medical Technologies. Assessment and Choice. 2024;(3):115-123

Structural, morphological and functional changes of diaphragm in patients with chronic heart failure. Russian Journal of Anesthesiology and Reanimatology. 2024;(5):88-95

Care algorithm for patients with chronic heart failure. Five steps to success. Russian Cardiology Bulletin. 2024;(3):6-15

A middle-aged patient with early manifestations of post-radiation constrictive pericarditis: case report. Russian Cardiology Bulletin. 2024;(3):98-103

Recent experimental and clinical studies in chronic heart failure (CHF) pointed on the dysregulation of circulating microRNA expression. The goal of this research was to evaluate diagnostic potential of microRNA in plasma of patients with CHF. Materials and methods. The level of circulating microRNA (21, 423-5р, 208а, 499а and 34а) were tested in plasma of 56 patients with CHF and 15 patients with cardiovascular pathologies without evidence of CHF (control group) using RT-PCR. Results. Biomarkers for the principal causes of CHF were found: dilatational cardiomyopathy (DCMP) and inflammatory cardiomyopathy (ICMP). It was shown that the level of microRNA-34a in patients with CHF caused by uncompensated hypertonic heart was 20.8 times lower in comparison with the control group (p=0.009). The level of microRNA-21 was 1.7 times higher in patients with CHF (p=0.022) and can be used as a biomarker for CHF (AUC 0.694 (CI =95% 0.550—0.838), threshold value 882.9 i.u., sensitivity and specificity — 52% and 87% respectively). Besides this, an inverse correlation was found between the level of microRNA-21 and stages of CHF according to Vasilenko VH and Starzhesko ND classification (r=–0.304, р=0.036). Plasma levels of microRNA-21 and microRNA-423-5p were 4.4 and 11.3 times higher in patients with ICMP, respectively. Plasma level of microRNA-21 in patients with DCMP was 1.7 times higher than in control group. Conclusion. We were able to show that plasma levels of microRNA-21 can be used as biomarkers of CHF, ICMP and DCMP; and plasma level of microRNA-423-5p can be used as biomarker of ICMP.

Keywords:

chronic heart failure

inflammatory cardiomyopathy

dilatational cardiomyopathy

microRNA

Authors:

Kochetov A.G.

Tsentr kardiokhirurgii i tsentr urologii 3-go Tsentral'nogo voennogo klinicheskogo gospitalia im. A.A. Vishnevskogo MO RF, Moskovskaia oblast', Krasnogorsk

Lyang O.V.

Assotsiatsija spetsialistov i organizatsij laboratornoj sluzhby «Federatsija laboratornoj meditsiny», 127083 Moskva, ul. 8 Marta, 1, str.12

Gimadiev R.R.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare of the Russian Federation

Abramov A.A.

National Cardiology Research Center, Russian Ministry of Health, 3 Cherepkovskaya 15A, Moscow, 121552, Russian Federation

Zhirov I.V.

National medical research center of cardiology MH RF

Skvortsov A.A.

Federal State Budget Organization National Medical Research Center of Cardiology, Ministry of Healthcare Russian Federation, Moscow, Russia

Zaseeva A.V.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare of the Russian Federation

Bosykh E.G.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare of the Russian Federation

Masenko V.P.

National Medical Research Center of Cardiology, Ministry of Healthcare of Russia

Tereshchenko S.N.

National medical research center of cardiology MH RF

List of references:

Raizman J, Diamandis E, Rayner K, Dimmeler S, Calin G, Thum T. Novel Biomarkers for Acute Myocardial Infarction: Is MicroRNA the New Kid on the Block? Clinical Chemistry. 2013;60(6):812-817. doi:10.1373/clinchem.2013.215491.
Kochetov A, Zhirov I, Masenko V, Gimadiev R, Lyang O, Tereshchenko S. Prospects of use of microRNAs in the diagnostics and treatment of heart failure. Kardiologicheskii vestnik. 9(2):62-67. (In Russ.)
Thum T, Galuppo P, Kneitz S et al. MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. Journal of Molecular and Cellular Cardiology. 2007;42(6):S154. doi:10.1016/j.yjmcc.2007.03.499.
Thum T, Galuppo P, Kneitz S et al. MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. Journal of Molecular and Cellular Cardiology. 2007;42(6):S154. doi:10.1016/j.yjmcc.2007.03.499.
Sheedy F, Palsson-McDermott E, Hennessy E et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nature Immunology. 2009;11(2):141-147. doi:10.1038/ni.1828.
Zhang Q, Xiao Z, He F, Zou J, Wu S, Liu Z. MicroRNAs Regulate the Pathogenesis of CVB3-Induced Viral Myocarditis. Intervirology. 2013;56(2):104-113. doi:10.1159/000343750.
Sabatel C, Malvaux L, Bovy N et al. MicroRNA-21 Exhibits Antiangiogenic Function by Targeting RhoB Expression in Endothelial Cells. PLoS ONE. 2011;6(2):e16979. doi:10.1371/journal.pone.0016979.
Tijsen A, Creemers E, Moerland P et al. MiR423-5p As a Circulating Biomarker for Heart Failure. Circulation Research. 2010;106(6):1035-1039. doi:10.1161/circresaha.110.218297.
Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis B, Amir O. Serum levels of microRNAs in patients with heart failure. European Journal of Heart Failure. 2012;14(2):147-154. doi:10.1093/eurjhf/hfr155.
Fan K, Zhang H, Shen J, Zhang Q, Li X. Circulating microRNAs levels in Chinese heart failure patients caused by dilated cardiomyopathy. Indian Heart Journal. 2013;65(1):12-16. doi:10.1016/j.ihj.2012.12.022.
Boon R, Iekushi K, Lechner S et al. MicroRNA-34a regulates cardiac ageing and function. Nature. 2013;495(7439):107-110. doi:10.1038/nature11919.
Lv P, Zhou M, He J et al. Circulating miR-208b and miR-34a Are Associated with Left Ventricular Remodeling after Acute Myocardial Infarction. IJMS. 2014;15(4):5774-5788. doi:10.3390/ijms15045774.
van Rooij E, Sutherland L, Qi X, Richardson J, Hill J, Olson E. Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA. Science. 2007;316(5824):575-579. doi:10.1126/science.1139089.
Wang J, Jiao J, Li Q et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nature Medicine. 2010;17(1):71-78. doi:10.1038/nm.2282.
Shieh J, Huang Y, Gilmore J, Srivastava D. Elevated miR-499 Levels Blunt the Cardiac Stress Response. PLoS ONE. 2011;6(5):e19481. doi:10.1371/journal.pone.0019481.
Satoh M, Minami Y, Takahashi Y, Tabuchi T, Nakamura M. A Cellular MicroRNA, let-7i, Is a Novel Biomarker for Clinical Outcome in Patients With Dilated Cardiomyopathy. Journal of Cardiac Failure. 2011;17(11):923-929. doi:10.1016/j.cardfail.2011.07.012.
Bauters C, Kumarswamy R, Holzmann A et al. Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. International Journal of Cardiology. 2013;168(3):1837-1840. doi:10.1016/j.ijcard.2012.12.074.
Nabiałek E, Wańha W, Kula D et al. Circulating microRNAs (miR-423-5p, miR-208a and miR-1) in acute myocardial infarction and stable coronary heart disease. Minerva Cardioangiol. 2013;61(6):627-637.
Goldraich L, Martinelli N, Matte U et al. Transcoronary gradient of plasma microRNA 423-5p in heart failure: evidence of altered myocardial expression. Biomarkers. 2014;19(2):135-141. doi:10.3109/1354750x.2013.870605.

Close metadata